- Home
- GLTO vs VMAR Comparison
GLTO vs VMAR Comparison
Compare GLTO & VMAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- VMAR
- Stock Information
- Founded
- GLTO 2011
- VMAR 1995
- Country
- GLTO Denmark
- VMAR Canada
- Employees
- GLTO N/A
- VMAR N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- VMAR Marine Transportation
- Sector
- GLTO Health Care
- VMAR Industrials
- Exchange
- GLTO Nasdaq
- VMAR Nasdaq
- Market Cap
- GLTO 4.4M
- VMAR 5.1M
- IPO Year
- GLTO 2020
- VMAR 2020
- Fundamental
- Price
- GLTO $3.35
- VMAR $6.64
- Analyst Decision
- GLTO Buy
- VMAR Strong Buy
- Analyst Count
- GLTO 1
- VMAR 1
- Target Price
- GLTO $10.00
- VMAR $2,700.00
- AVG Volume (30 Days)
- GLTO 18.8K
- VMAR 35.0K
- Earning Date
- GLTO 08-11-2025
- VMAR 07-14-2025
- Dividend Yield
- GLTO N/A
- VMAR N/A
- EPS Growth
- GLTO N/A
- VMAR N/A
- EPS
- GLTO N/A
- VMAR N/A
- Revenue
- GLTO N/A
- VMAR $1,612,492.00
- Revenue This Year
- GLTO N/A
- VMAR N/A
- Revenue Next Year
- GLTO N/A
- VMAR $264.29
- P/E Ratio
- GLTO N/A
- VMAR N/A
- Revenue Growth
- GLTO N/A
- VMAR N/A
- 52 Week Low
- GLTO $2.01
- VMAR $4.04
- 52 Week High
- GLTO $16.07
- VMAR $1,025.33
- Technical
- Relative Strength Index (RSI)
- GLTO 65.19
- VMAR 40.84
- Support Level
- GLTO $3.19
- VMAR $7.18
- Resistance Level
- GLTO $3.63
- VMAR $8.13
- Average True Range (ATR)
- GLTO 0.24
- VMAR 0.65
- MACD
- GLTO 0.01
- VMAR -0.18
- Stochastic Oscillator
- GLTO 79.37
- VMAR 16.08
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About VMAR Vision Marine Technologies Inc.
Vision Marine Technologies Inc is in the business of designing and manufacturing electric outboard powertrain systems, power boats, and related technology and the renting of electric boats. The different models of the powerboats and electric boats manufactured by the company include Bruce 22, Fantail 217, Volt 180, and others. The company operates in two reportable business segments; Sale of electric boats and Rental of electric boats. The majority of the revenue for the company is generated from the Sale of electric boats segment. Geographically, the company generates revenue from its business in Canada, USA and other countries. A substantial portion of the overall revenue is generated from its business in USA.